Impact of VISION and TheraP Imaging Criteria on Outcomes of 177 Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #OP-367; Pres time: Oct 19, 2026; 09:45 AM - 11:15 AM; Location: Hall C; "VISION criteria encompass the majority of real-world patients eligible for 177Lu-PSMA-617, whereas TheraP criteria select a more favorable subgroup with deeper PSA responses. FDG+/PSMA− mismatch remains the strongest adverse imaging biomarker, supporting the value of dual-tracer PET in selected patients."
Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
N. Hasan 1; M. Krim 1; D. Vallot 1; J. Texier 2; M. Bros 1; L. Vija 1; T. Cassou-Mounat 1; C. Lamesa 1; F. Courbon 1
|